<DOC>
	<DOCNO>NCT02483182</DOCNO>
	<brief_summary>This phase II , prospective , randomize , double-blind , parallel group , acyclovir-controlled clinical study evaluate safety , tolerability preliminary therapeutic efficacy ZEP-3 ointment 1.0 % treatment cold sore ( Herpes labialis ) , follow five consecutive treatment day five time daily topical administration .</brief_summary>
	<brief_title>Safety , Tolerability Therapeutic Efficacy Topical ZEP-3 Ointment ( 1.0 % ) Treatment Cold Sores</brief_title>
	<detailed_description>The primary endpoint study : - `` Time healing '' - Clinician-assessed duration day herpes labialis episode . - Patient-assessed duration intensity pain Visual Analog Scale ( VAS ) . - Safety tolerability follow five consecutive treatment day five time daily topical administration . The secondary endpoint study : - Proportion subject non - ulcerative herpes lesion . - Time herpes labialis recurrence Subject safety assess follow treatment ZEP-3 ointment 1.0 % acyclovir cream 5 % treatment , use measurement follow variable : - Physical examination , - Vital Signs ( HR , BP , Body temperature ) , - Adverse event record - Concomitant medication</detailed_description>
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Prior enrollment study , candidate must meet ALL follow inclusion criterion : 1 . Patients suffer recurrent Herpes labialis history least 3 cold sore recurrences previous 12 month . 2 . Participants , either male female 18 75 year age . 3 . Patients arrive clinic symptom acute Herpes labialis episode . Or , patient arrive clinic within 48 hour treatment initiation recurrent Herpes labialis episode . 4 . Patients previous Herpes labialis episode must heal least 14 day baseline visit 5 . Patients history reaction topical product . 6 . Female subject childbearing potential must negative pregnancy test screen agree use proper contraceptive method study . 7 . Participant understands nature procedure willing able comply requirement protocol . 8 . Patient willing able provide write informed consent prior study procedure . 1 . Subject abnormal skin condition significant facial hair near investigational area 2 . Subject body pierce around area ordinarily affect cold sore . 3 . Subjects history cardiac abnormality . 4 . Subject recent history renal dysfunction serious hepatic disease 5 . Subject active malignancy immunodeficient disease 6 . Subject unwilling stop use topical medical , OTC , cosmetic facial skin care product around oral area study period . 7 . Subject require chronic use immunomodifying drug topical steroid near face . 8 . Subject require chronic use antiviral medication . 9 . Subject require chronic use analgesic , pain medication nonsteroidal anti inflammatory agent ( NSAIDs ) . 10 . History allergic adverse response acyclovir , related antiviral drug . 11 . Subject infection HSV1 isolate know resistant acyclovir , valacyclovir , famciclovir , ganciclovir . 12 . Subject herpes vaccine . 13 . Females pregnancy , lactation breastfeeding . 14 . Subject history alcoholism drug abuse within precede 12 month . 15 . Subject currently enrol another clinical trial involve use drug and/or device . 16 . Any history , Investigator 's judgment , make subject ineligible place subject undue risk . 17 . Subjects immune deficiency condition include acquire immune deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Herpes labialis , Cold sores , ZEP-3 ointment</keyword>
</DOC>